Prove its efficacy and safety first


(FILES) In this file photo taken on October 17, 2018, a marijuana plant is pictured in Vancouver, Canada. - Canadian cannabis producer Aphria on Friday, December 28, 2018 rejected a proposed Can2.8 billion (2.1 billion US) takeover bid by US-based Xanthic Biopharma, calling it hostile and under-valued. Green Growth Brands, a division of Xanthic Biopharma, presented a conditional offer of Can11 per share on December 27, 2018 after markets closed. (Photo by Don MacKinnon / AFP)

THE Star Online last week reported the Deputy Health Minister of Malaysia’s response to Thailand approving marijuana for medical use and research (tinyurl.com/star-cannabis). Marijuana is also known as cannabis, or ganja in Malay.

Accor­ding to Deputy Minister Dr Lee Boon Chye, pharmaceutical firms wishing to register the drug for such use must provide the required standard information on its quality, efficacy and safety.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Letters

Enough checks and balances
Solutions to overcrowded schools
New account a valuable tool
Reduce medication waste by redistributing it to those in need
Well done to our Malaysian badminton players for a gallant effort
All for sustainable tourism
Redefining success and education
History as a solution to national unity
BPA-free yet still toxic?
In solidarity with US campus protests

Others Also Read